PT3114139T - Anticorpos anti-eotaxina-2 que reconhecem quimiocinas adicionais de ligação a ccr3 - Google Patents
Anticorpos anti-eotaxina-2 que reconhecem quimiocinas adicionais de ligação a ccr3Info
- Publication number
- PT3114139T PT3114139T PT157149634T PT15714963T PT3114139T PT 3114139 T PT3114139 T PT 3114139T PT 157149634 T PT157149634 T PT 157149634T PT 15714963 T PT15714963 T PT 15714963T PT 3114139 T PT3114139 T PT 3114139T
- Authority
- PT
- Portugal
- Prior art keywords
- antibodies
- recognize additional
- binding chemokines
- ccr3
- anti eotaxin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461947852P | 2014-03-04 | 2014-03-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3114139T true PT3114139T (pt) | 2022-09-13 |
Family
ID=52815066
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT157149634T PT3114139T (pt) | 2014-03-04 | 2015-03-04 | Anticorpos anti-eotaxina-2 que reconhecem quimiocinas adicionais de ligação a ccr3 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10246508B2 (https=) |
| EP (2) | EP3114139B1 (https=) |
| JP (1) | JP6553075B2 (https=) |
| CN (1) | CN106103479B (https=) |
| BR (1) | BR112016020366B1 (https=) |
| DK (1) | DK3114139T3 (https=) |
| ES (1) | ES2926700T3 (https=) |
| IL (1) | IL247219B (https=) |
| PT (1) | PT3114139T (https=) |
| RU (1) | RU2705255C2 (https=) |
| WO (1) | WO2015132790A2 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017183028A1 (en) * | 2016-04-18 | 2017-10-26 | Chemomab Ltd. | Eotaxin-2 inhibitors in the treatment of fibromyalgia |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| CA3045310A1 (en) | 2016-12-14 | 2018-06-21 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| ES3052981T3 (en) | 2017-01-24 | 2026-01-16 | Kyowa Kirin Co Ltd | Therapeutic or prophylactic agent for treating radiation damage |
| GB201702500D0 (en) * | 2017-02-16 | 2017-04-05 | Univ Sheffield | Stable vamp reporter assay |
| IL251024A0 (en) * | 2017-03-08 | 2017-06-29 | Chemomab Ltd | Antibodies against eutaxin 2 for use in the treatment of liver diseases |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| US10945904B2 (en) | 2019-03-08 | 2021-03-16 | Auris Health, Inc. | Tilt mechanisms for medical systems and applications |
| CN121197633A (zh) | 2019-12-13 | 2025-12-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
| US20230192836A1 (en) | 2020-04-20 | 2023-06-22 | Chemomab Ltd. | Ccl24 inhibitors in the treatment of covid-19 |
| CA3172627A1 (en) | 2020-04-22 | 2021-10-28 | Adi Mor | Method of treatment using anti-ccl24 antibody |
| EP4143227A2 (en) * | 2020-04-30 | 2023-03-08 | Sairopa B.V. | Anti-cd103 antibodies |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303736B1 (it) * | 1998-11-11 | 2001-02-23 | San Raffaele Centro Fond | Peptidi derivati da rantes con attivita' anti-hiv. |
| US7999119B2 (en) * | 2006-07-22 | 2011-08-16 | Oxagen Limited | Compounds having CRTH2 antagonist activity |
| JP2012516150A (ja) * | 2009-01-28 | 2012-07-19 | ザ メディカル リサーチ，インフラストラクチュア，アンド ヘルス サービシーズ ファンド オブ ザ テル アビブ メディカル センター | 炎症性疾患、自己免疫疾患及び循環器疾患におけるエオタキシン−２（ｃｃｌ２４）阻害剤 |
| DK2470671T3 (en) * | 2009-08-28 | 2015-02-09 | Regeneron Pharma | ANTIKIN- ANTIBODIES BINDING TO MULTIPLE CC chemokines |
| GB201103837D0 (en) * | 2011-03-07 | 2011-04-20 | Oxagen Ltd | Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid |
-
2015
- 2015-03-04 PT PT157149634T patent/PT3114139T/pt unknown
- 2015-03-04 JP JP2016555467A patent/JP6553075B2/ja active Active
- 2015-03-04 CN CN201580011755.4A patent/CN106103479B/zh active Active
- 2015-03-04 WO PCT/IL2015/050234 patent/WO2015132790A2/en not_active Ceased
- 2015-03-04 BR BR112016020366-6A patent/BR112016020366B1/pt active IP Right Grant
- 2015-03-04 EP EP15714963.4A patent/EP3114139B1/en active Active
- 2015-03-04 ES ES15714963T patent/ES2926700T3/es active Active
- 2015-03-04 US US15/122,241 patent/US10246508B2/en active Active
- 2015-03-04 RU RU2016136639A patent/RU2705255C2/ru active
- 2015-03-04 DK DK15714963.4T patent/DK3114139T3/da active
- 2015-03-04 EP EP22165244.9A patent/EP4155317A1/en active Pending
-
2016
- 2016-08-10 IL IL247219A patent/IL247219B/en unknown
-
2019
- 2019-02-07 US US16/270,231 patent/US10479830B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017508461A (ja) | 2017-03-30 |
| EP3114139B1 (en) | 2022-06-15 |
| EP4155317A1 (en) | 2023-03-29 |
| BR112016020366B1 (pt) | 2024-01-02 |
| RU2016136639A (ru) | 2018-04-05 |
| CN106103479B (zh) | 2019-12-24 |
| US10479830B2 (en) | 2019-11-19 |
| IL247219A0 (en) | 2016-09-29 |
| RU2705255C2 (ru) | 2019-11-06 |
| US20160368979A1 (en) | 2016-12-22 |
| WO2015132790A3 (en) | 2015-11-05 |
| EP3114139A2 (en) | 2017-01-11 |
| US20190153088A1 (en) | 2019-05-23 |
| ES2926700T3 (es) | 2022-10-27 |
| CN106103479A (zh) | 2016-11-09 |
| WO2015132790A2 (en) | 2015-09-11 |
| DK3114139T3 (da) | 2022-09-12 |
| JP6553075B2 (ja) | 2019-08-07 |
| IL247219B (en) | 2021-09-30 |
| RU2016136639A3 (https=) | 2018-05-04 |
| US10246508B2 (en) | 2019-04-02 |
| BR112016020366A2 (pt) | 2018-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252004A0 (en) | Ether-substituted antibody | |
| IL250583A0 (en) | Anti-tigit antibodies | |
| IL252422B (en) | Effector-deficient anti-cd32a antibodies | |
| SG11201703403TA (en) | Anti-tim-3 antibodies | |
| SG11201703346PA (en) | Anti-tim-3 antibodies | |
| LT3221346T (lt) | Antikūnai, apimantys modifikuotas sunkiosios grandinės pastoviąsias sritis | |
| IL247219A0 (en) | Antibodies against aolexin 2 that identify as additional cytokines that bind to ccr3 | |
| GB201410825D0 (en) | Anti-axl antibodies | |
| GB201410826D0 (en) | Anti-axl antibodies | |
| GB201410520D0 (en) | Antibody | |
| IL248220A0 (en) | Anti- nme antibody | |
| ZA201604640B (en) | Novel anti-netrin-1 antibody | |
| IL250374B (en) | Antibodies against ceramide | |
| IL247988A0 (en) | Antibodies against hpa–1a | |
| SG11201700922YA (en) | Anti-orai1 antibody | |
| PL3112463T3 (pl) | Nowe przeciwciało przeciwko presepsynie | |
| GB201418776D0 (en) | Antibody | |
| GB201413745D0 (en) | Antibody | |
| GB201411319D0 (en) | Antibody | |
| GB201407535D0 (en) | Antibody Drug - Conjugates | |
| GB201419089D0 (en) | Anti-TIM-3 antibodies | |
| GB201419092D0 (en) | Anti-TIM-3 antibodies | |
| GB201417614D0 (en) | Antibodies | |
| GB201414270D0 (en) | Antibodies | |
| GB201405775D0 (en) | Antibodies |